Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17876592 | 0.93 | CYP2C9 (0.72) | CYP2C9CYP2C19CYP3A4CHRM2EPHX2 | |
| SCHEMBL17876646 | 0.92 | CYP2C9 (0.71) | CYP2C9CYP2C19CYP3A4CHRM2EPHX2 | |
| SCHEMBL17876664 | 0.92 | CYP2C9 (0.71) | CYP2C9CYP2C19CYP3A4CHRM2EPHX2 | |
| SCHEMBL20346932 | 0.92 | CYP2C9 (0.71) | CYP2C9CYP2C19CYP3A4CHRM2EPHX2 | |
| SCHEMBL13838235 | 0.92 | CYP2C9 (0.71) | CYP2C9CYP2C19CYP3A4CHRM2EPHX2 | |
| SCHEMBL17876633 | 0.91 | CYP2C9 (0.70) | CYP2C9CYP2C19CYP3A4CHRM2EPHX2 | |
| SCHEMBL17876524 | 0.91 | CYP2C9 (0.62) | CYP2C9CYP2C19CYP3A4LMNA | |
| SCHEMBL17876545 | 0.91 | CYP2C9 (0.69) | CYP2C9CYP2C19CYP3A4CHRM2EPHX2 | |
| SCHEMBL17876561 | 0.90 | CYP2C9 (0.61) | CYP2C9CYP2C19CYP3A4CHRM2 | |
| SCHEMBL17876658 | 0.90 | CYP2C9 (0.73) | CYP2C9CYP2C19CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185774-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | CYP2C9 4235/4885CYP2C19 4181/4885CYP3A4 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.